Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life.
ACT, Asthma Control Test
Anti IL-5
CI, Confidence Intervals
COPD, chronic obstructive pulmonary disease
Comorbidities
FeNO, fractional nitric oxide
GERD, gastroesophageal reflux disease
ICS, inhaled corticosteroids
IQR, interquartile range
LABA, long acting beta 2 agonist
LAMA, long acting muscarinic antagonist
LOS, Length of stay
MEP, Mepolizumab
Mepolizumab
OCS
OCS, Oral Corticosteroids
OR, Odds Ratio
Pharmacoeconomics
RCTs, Randomized Controlled Trials
RR, Rate Ratio
SD, Standard Deviation
Severe asthma
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
14
05
2020
revised:
08
12
2020
accepted:
29
12
2020
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
19
2
2021
Statut:
epublish
Résumé
Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients' health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of working days lost due to the disease. The primary objective was to compare the annual total cost per patient pre- and post-MEP. Secondary outcomes included rates of exacerbations and number of OCS-dependent patients. 106 patients were enrolled in the study: 46 male, median age 58 years. Mean annual cost pre- and post-MEP (cost of biologic excluded) was €3996 and €1,527, respectively. Total savings due to MEP resulted in €2469 (95%CI 1945-2993), 62% due to exacerbations reduction and 33% due to productivity increase. Such savings could fund about 22% of the total cost of MEP for one year. The introduction of MEP induced a clinical benefit by reducing both OCS-dependent patients (OR = 0.12, 95%CI 0.06-0.23) and exacerbation rate (RR = 0.19, 95%CI 0.15-0.24). Patients with severe eosinophilic asthma experienced a clinical benefit in asthma control adding MEP to standard therapy. Biologic therapy can be, partially, funded by the savings produced by patients' improvement.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients' health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients.
METHODS
METHODS
Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of working days lost due to the disease. The primary objective was to compare the annual total cost per patient pre- and post-MEP. Secondary outcomes included rates of exacerbations and number of OCS-dependent patients.
RESULTS
RESULTS
106 patients were enrolled in the study: 46 male, median age 58 years. Mean annual cost pre- and post-MEP (cost of biologic excluded) was €3996 and €1,527, respectively. Total savings due to MEP resulted in €2469 (95%CI 1945-2993), 62% due to exacerbations reduction and 33% due to productivity increase. Such savings could fund about 22% of the total cost of MEP for one year. The introduction of MEP induced a clinical benefit by reducing both OCS-dependent patients (OR = 0.12, 95%CI 0.06-0.23) and exacerbation rate (RR = 0.19, 95%CI 0.15-0.24).
CONCLUSIONS
CONCLUSIONS
Patients with severe eosinophilic asthma experienced a clinical benefit in asthma control adding MEP to standard therapy. Biologic therapy can be, partially, funded by the savings produced by patients' improvement.
Identifiants
pubmed: 33598095
doi: 10.1016/j.waojou.2021.100509
pii: S1939-4551(21)00003-X
pmc: PMC7846931
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100509Investigateurs
Gabriella Guarnieri
(G)
Vincenzo Patella
(V)
Foschino Barbaro Maria Pia
(FB)
Elisiana Carpagnano
(E)
Anna Del Colle
(AD)
Giulia Scioscia
(G)
Pelaia Gerolamo
(P)
Pierluigi Paggiaro
(P)
Manuela Latorre
(M)
Francesca Puggioni
(F)
Francesca Racca
(F)
Elisabetta Favero
(E)
Sandra Iannacone
(S)
Eleonora Savi
(E)
Marcello Montagni
(M)
Gianna Camiciottoli
(G)
Chiara Allegrini
(C)
Giuseppe Spadaro
(G)
Caterina Detoraki
(C)
Carla Galeone
(C)
Patrizia Ruggiero
(P)
Monna Rita Yacoub
(MR)
Alvise Berti
(A)
Gisella Colombo
(G)
Nicola Scichilone
(N)
Carmen Durante
(C)
Maria Teresa Costantino
(MT)
Chiara Roncallo
(C)
Mariachiara Braschi
(M)
Francesco Blasi
(F)
Alice D'Adda
(A)
Erminia Ridolo
(E)
Massimo Triggiani
(M)
Roberta Parente
(R)
D'Amato Maria
(D)
Maria Vittoria Verrillo
(MV)
Zappa Maria Cristina
(ZM)
Marianna Lilli
(M)
Nunzio Crimi
(N)
Marco Bonavia
(M)
Angelo Guido Corsico
(AG)
Amelia Grosso
(A)
Stefano Del Giacco
(S)
Margherita Deidda
(M)
Luisa Ricciardi
(L)
Stefania Isola
(S)
Francesca Cicero
(F)
Giuliana Amato
(G)
Federica Vita
(F)
Antonio Spanevello
(A)
Patrizia Pignatti
(P)
Francesca Cherubino
(F)
Dina Visca
(D)
Eleonora Aletti
(E)
Fabio Luigi Massimo Ricciardolo
(FL)
Vitina Maria Anna Carriero
(VM)
Francesca Bertolini
(F)
Pierachille Santus
(P)
Roberta Barlassina
(R)
Andrea Airoldi
(A)
Giuseppe Guida
(G)
Nucera Eleonora
(N)
Arianna Aruanno
(A)
Angela Rizzi
(A)
Cristiano Caruso
(C)
Stefania Colantuono
(S)
Alessandra Arcolaci
(A)
Andrea Vianello
(A)
Fulvia Chieco Bianchi
(FC)
Maria Rita Marchi
(MR)
Stefano Centanni
(S)
Simone Luraschi
(S)
Silvia Ruggeri
(S)
Rocco Rinaldo
(R)
Elena Parazzini
(E)
Cecilia Calabrese
(C)
Martina Flora
(M)
Lorenzo Cosmi
(L)
Linda Di Pietro
(L)
Enrico Maggi
(E)
Laura Pini
(L)
Luigi Macchia
(L)
Danilo Di Bona
(D)
Luca Richeldi
(L)
Carola Condoluci
(C)
Leonello Fuso
(L)
Matteo Bonini
(M)
Alessandro Farsi
(A)
Giulia Carli
(G)
Paolo Montuschi
(P)
Giuseppe Santini
(G)
Maria Elisabetta Conte
(ME)
Elisa Turchet
(E)
Carlo Barbetta
(C)
Francesco Mazza
(F)
Simona D'Alo
(S)
Stefano Pucci
(S)
Maria Filomena Caiaffa
(MF)
Elena Minenna
(E)
Luciana D'Elia
(L)
Carlo Pasculli
(C)
Vittorio Viviano
(V)
Paolo Tarsia
(P)
Joyce Rolo
(J)
Mariacarmela Di Proietto
(M)
Salvatore Lo Cicero
(S)
Mariacarmela Di Proietto
(M)
Informations de copyright
© 2021 The Authors.
Références
Clin Mol Allergy. 2017 Apr 10;15:9
pubmed: 28400707
J Investig Allergol Clin Immunol. 2016;26(4):256-62
pubmed: 27373924
Pulm Pharmacol Ther. 2019 Oct;58:101836
pubmed: 31473366
Respir Med. 2014 Feb;108(2):271-7
pubmed: 24406243
Int Forum Allergy Rhinol. 2015 Sep;5 Suppl 1:S7-10
pubmed: 26010063
N Engl J Med. 2014 Sep 25;371(13):1198-207
pubmed: 25199059
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
World Allergy Organ J. 2019 Jan 26;12(1):100007
pubmed: 30937132
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1462-1468
pubmed: 30368004
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):120-9.e3
pubmed: 26439182
Curr Opin Allergy Clin Immunol. 2019 Feb;19(1):61-67
pubmed: 30407207
Ann Allergy Asthma Immunol. 2017 Feb;118(2):220-225
pubmed: 27923549
Eur Respir J. 2018 Oct 25;52(4):
pubmed: 30190274
World Allergy Organ J. 2018 Dec 6;11(1):34
pubmed: 30555618
N Engl J Med. 2014 Sep 25;371(13):1189-97
pubmed: 25199060
J Asthma Allergy. 2020 Jan 29;13:77-87
pubmed: 32099413
Allergy Asthma Proc. 2019 May 1;40(3):146-153
pubmed: 30925945
Pharmacoeconomics. 2018 Feb;36(2):131-144
pubmed: 28933002
Lancet. 2012 Aug 18;380(9842):651-9
pubmed: 22901886
Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):121-131
pubmed: 28277854
J Asthma. 2018 Feb;55(2):208-219
pubmed: 28586296
Farm Hosp. 2019 Nov 01;43(6):187-193
pubmed: 31705642
Biomed Res Int. 2018 Nov 5;2018:5698212
pubmed: 30519580
Allergy. 2019 Dec;74(12):2539-2541
pubmed: 31166605